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dependent on its catalytically active cysteine, but independ-
ent of its noncanonical pathway modulated by its N-termi-
nal domain in primary neurons. Otub1 strongly increased 
AT8-positive Tau and oligomeric Tau forms and increased 
Tau-seeded Tau aggregation in primary neurons. Finally, 
we demonstrated that expression of Otub1 but not its cata-
lytically inactive form induced pathological Tau forms after 
2 months in Tau transgenic mice in vivo, including AT8-
positive Tau and oligomeric Tau forms. Taken together, we 
here identified Otub1 as a Tau deubiquitinase in vitro and 
in vivo, involved in formation of pathological Tau forms, 
including small soluble oligomeric forms. Otub1 and par-
ticularly Otub1 inhibitors, currently under development 
for cancer therapies, may therefore yield interesting novel 
therapeutic avenues for Tauopathies and AD.
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of 
dementia, being characterized by progressive accumulation 
of amyloid plaques and neurofibrillary tangles, composed 
of aggregated Aβ and hyperphosphorylated Tau, respec-
tively [9, 69]. Over the last decade, Tau has emerged as an 
important therapeutic target. This is underscored by (i) the 
close correlation of Tau pathology with the progression of 
symptoms and (ii) the existence of a family of Tauopathies 
which are neurodegenerative disorders characterized by Tau 
aggregation spatiotemporally correlating with brain dys-
function and associated symptoms, as well as, most impor-
tantly, (iii) the identification of mutations in Tau causally 
Abstract Dysregulated proteostasis is a key feature of 
a variety of neurodegenerative disorders. In Alzheimer’s 
disease (AD), progression of symptoms closely corre-
lates with spatiotemporal progression of Tau aggregation, 
with “early” oligomeric Tau forms rather than mature 
neurofibrillary tangles (NFTs) considered to be pathoge-
netic culprits. The ubiquitin–proteasome system (UPS) 
controls degradation of soluble normal and abnormally 
folded cytosolic proteins. The UPS is affected in AD and 
is identified by genomewide association study (GWAS) 
as a risk pathway for AD. The UPS is determined by bal-
anced regulation of ubiquitination and deubiquitination. 
In this work, we performed isobaric tags for relative and 
absolute quantitation (iTRAQ)-based Tau interactome map-
ping to gain unbiased insight into Tau pathophysiology and 
to identify novel Tau-directed therapeutic targets. Focusing 
on Tau deubiquitination, we here identify Otub1 as a Tau-
deubiquitinating enzyme. Otub1 directly affected Lys48-
linked Tau deubiquitination, impairing Tau degradation, 
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linked to Tauopathies, demonstrating a causal executive 
role of Tau in Tauopathies. Although Tau aggregation is 
closely linked to symptom progression, smaller oligomeric 
Tau forms rather than mature full-blown neurofibrillary 
tangles (NFTs) are generally considered to be pathogenetic 
culprits in the disease process [6, 11, 12, 15, 20, 33, 37, 
39, 40, 59, 60, 67, 70]. Accumulation of misfolded and 
aggregated proteins is a key feature of a variety of neuro-
degenerative disorders, raising interest in understanding 
clearance and degradation mechanisms of these pathoge-
netic culprits [7, 22, 28, 35, 42, 43]. The UPS selectively 
degrades normal and abnormally folded soluble proteins, 
which are tagged by ubiquitin for elimination [22], while 
the autophagic–lysosomal system (ALS) mainly degrades 
large protein aggregates or inclusions and organelles. With 
smaller soluble Tau forms considered to be toxic culprits, 
the UPS represents an important target for therapeutic 
interventions and is the main focus of this work.
The UPS is reported to be downregulated in various neu-
rodegenerative disorders, with increased proteasome activ-
ity shown to be beneficial in related disease models [15, 28, 
42, 52]. The presence of ubiquitinated Tau in pathological 
lesions of AD provided the first lead implicating the UPS 
in AD and Tauopathies [49, 50]. In AD patients’ brain, 
paired helical filaments (PHFs) were found to be associated 
with impaired proteasome activity in a brain-region spe-
cific way [15, 28, 34, 35]. Furthermore, a ubiquitin mutant 
called UBB+1, with a 19-AA extension, has been identified 
in neurons from AD patients and suppresses UPS func-
tion [38, 45, 71]. UBB+1-induced proteasome dysfunction 
resulted in Tau pathology and related neuronal dysfunction 
in transgenic mice expressing UBB+1 [29]. Accumulating 
evidence indicates that the UPS is implicated in clearance 
of different Tau forms and its dysfunction is closely related 
to Tau aggregation and accumulation [1, 13–16, 25, 46, 57, 
68]. Conversely, Tau accumulation was recently shown to 
impair proteasomal degradation, suggesting a vicious cir-
cle [52]. Degradation of target proteins through the UPS is 
regulated by ubiquitination, with differently linked (Lys6, 
Lys11, Lys48, and Lys63) polyubiquitinated Tau identified 
in AD brains and models [13, 49–51, 56]. Different Tau 
forms can be ubiquitinated by E3 ligases CHIP [57, 63], 
TRAF6 [1], and MARCH7 [19], with particularly CHIP/
Hsp70-dependent polyubiquitination characterized in detail 
in vitro and in vivo. Ubiquitination is highly dynamic and 
reversible by the action of deubiquitinating enzymes known 
as deubiquitinases (DUBs), hence being determined by bal-
anced regulation between ubiquitination and deubiquitina-
tion. While Tau ubiquitination has been studied intensively, 
its deubiquitination remains less well explored.
Deubiquitinases are attracting increasing interest as 
therapeutic targets. Otub1 is an ovarian-tumor domain 
cysteine protease deubiquitinating enzyme [2] with strong 
preference for Lys48-linked polyubiquitin chains over 
Lys11-, Lys29-, or Lys63-linked polyubiquitin chains in 
the canonical pathway, dependent on its highly conserved 
active-site cysteine (C91) [17, 48, 74]. Recently, a nonca-
nonical pathway of Otub1, involved in DNA double-strand 
break response by modulating Lys63 polyubiquitin chain 
formation, was highlighted [31, 53, 77, 78]. Otub1 has 
been implicated in a broad range of cellular pathways such 
as IL-1β-induced inflammation and stabilization of proteins 
including c-IAP1, p53, TRAF3/6, SMAD2/3, and RhoA, 
indicating that it is an important regulator in different phys-
iological processes [23, 26, 32, 44, 66], while its role in the 
nervous system remains unknown.
In this study, we performed iTRAQ-based Tau interac-
tome mapping to identify Tau-interacting proteins with 
Tau-modifying potential as therapeutic targets. This high-
lighted Otub1 as a potential entry point to better understand 
the link between the UPS and Tauopathies. We demonstrate 
here for the first time that Tau is deubiquitinated by Otub1. 
We demonstrate that Otub1 regulates levels of Lys48-linked 
ubiquitin-conjugated Tau and increases pathological forms 
of Tau in vitro and in vivo.
Materials and methods
Animals
TauP301S (PS19) mice [81] were bred and used in our labo-
ratory as reported previously [64, 65, 72]. The mice bred in 
our laboratory develop Tau pathology and a neurodegenerative 
phenotype starting at around ~10–11 months. In this study, 
stereotactic injections were performed at P0 and age-matched 
littermates were used for analysis 2 months postinjection. At 
the age of 2 months, no Tau pathology or AT8-positive stain-
ing is detected in TauP301S mice in our colony. All experi-
ments were performed in compliance with protocols approved 
by the UCLouvain Ethical Committee for Animal Welfare.
Reagents and antibodies
MG132 and cycloheximide were purchased from Sigma. 
Phosphatase inhibitor (PhosSTOP™) and protease inhibi-
tor cocktails (cOmplete™, Mini, EDTA-free) were obtained 
from Roche. Primary antibodies used in this study included 
antibodies directed against human Tau (Dako), Otub1, Ubiq-
uitin-Lys48-specific, Ubiquitin-Lys63-specific (Abcam), 
Phospho-Tau (Ser202/Thr205) AT8, Phospho-Tau (Thr231) 
AT180, Phospho-Tau (Thr212/Ser214) AT100 (Thermo 
Fisher Scientific), and Oligomeric-Tau T22 (Merck), applied 
in combination with appropriate horseradish peroxidase 




Cell culture and transfection
Human kidney-derived QBI-293 were originally obtained 
from QBiogene (Carlsbad, CA, USA) and HEK293 cells from 
American Type Culture Collection (ATCC), and were cultured 
according to the manufacturer’s protocol. All cells were main-
tained at 37 °C in humidified atmosphere with 5% CO2. Cells 
were transfected with plasmids expressing Otub1, USP9x, 
USP5 or empty vector using FuGENE® 6 (Roche) or short 
interfering RNAs (siRNAs) using Lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s protocol. For analysis 
of the effects on Tau or on Tau-seeded Tau aggregation, trans-
fection was performed 24 h before starting the assay.
In vivo gene delivery
Adeno-associated viral (AAV) vectors expressing wild-
type Otub1 fused with a green fluorescent protein (GFP) 
tag (AAV–Otub1) or expressing GFP (AAV–GFP) driven 
by neuron-specific Syn promoter were generated using a 
previously described plasmid (Addgene, plasmid #26976). 
Mutant Otub1 C91A and N-terminal truncation (N-T) were 
generated by molecular cloning starting from the WT-
Otub1 construct. AAV viruses were produced in HEK-AAV 
cells using AAV-DJ8 kit (Cell Biolabs, Inc.), and subse-
quently purified and concentrated by iodixanol-based ultra-
centrifugation. AAV titer was tested using a QuickTiter™ 
AAV Quantitation Kit (Cell Biolabs, Inc). For P0 injection, 
each mouse was injected into the lateral ventricles of both 
cerebral hemispheres with 4.2 × 109 total viral particles 
per side, TauP301S transgenic mice were euthanized, and 
brains were dissected as described previously following 
transcardial flushing and analyzed at 2 months postinjec-
tion [64, 65, 72].
Immunoprecipitation and Western blot analysis
To detect Tau ubiquitination, primary neurons were infected 
with AAV–Otub1 (wild type; catalytically dead mutant 
C91A; N-terminal truncation) or AAV–GFP, five days after 
infection, cells were washed with phosphate-buffered saline 
(PBS) and lysed in TGN lysis buffer (50 mM Tris HCl, pH 
7.5, 200 mM NaCl, 50 mM sodium β-glycerophosphate, 
1% Tween 20, 0.2% NP40) containing phosphatase inhibi-
tor (PhosSTOP™; Roche) and protease inhibitor cocktails 
(cOmplete™, Mini, EDTA-free; Roche) at 4 °C for 30 min 
on a wheel rotor, and spun at 12,000×g for 15 min. Fol-
lowing preclearing without antibodies at 4 °C for 1 h, the 
supernatants were incubated with specific antibodies for 
1 h at 4 °C, followed by incubation with protein A-Sepha-
rose beads at 4 °C for 45 min. Following stringent washing 
with TGN buffer and PBS, immunoprecipitated proteins 
were analyzed by immunoblotting.
For Western blot analysis, cells were washed twice with 
PBS and extracted for 30 min at 4 °C with Triton lysis 
buffer (1% Triton X-100, 50 mM Tris, 150 mM NaCl, pH 
7.6) containing protease and phosphatase inhibitors, and 
centrifuged at 12,000×g for 15 min at 4 °C to remove 
insoluble material. Protein content was determined by BCA 
Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, 
USA). Samples (10 μg) were separated using precast 8% 
Tris–glycine gels or 4–12% Bis–Tris gels (MOPS running; 
Invitrogen) and transferred to polyvinylidene difluoride 
membranes. Immunoblotting was performed using the 
indicated primary antibodies with corresponding second-
ary antibodies, and developed using ECL kit (PerkinElmer, 
Waltham, MA, USA).
Tau aggregation assay
Tau PFFs (synthetic preformed fibrils), referred to as “Tau 
seeds,” were generated as described previously [24, 65, 
72]. Truncated human Tau fragments bearing a proaggrega-
tion mutant (Tau-P301L) containing the four-repeat domain 
[K18; Q244-E372 (4RTau)], N-terminally Myc-tagged were 
produced in Escherichia coli (TEBU-Bio). Tau-PFFs were 
obtained by incubation of Tau fragments (66 μM) at 37 °C 
for 5 days in presence of heparin (133 μM) in 100 mM 
ammonium acetate buffer (pH 7.0), spun down (100,000×g, 
1 h, 4 °C), resuspended to 333 μM, and sonicated before use.
In vitro Tau aggregation assay in HEK293 cells: PFF-
induced Tau aggregation in vitro was performed essentially 
as described previously [24, 65, 72]. Sonicated Tau seeds 
were diluted in 100 mM ammonium acetate buffer (pH 
7.0) to 10 µM solution and sonicated with 8 pulses/30% 
amplitude and added to the cells using BioPORTER® 
(AMS Biotechnology, Milton, UK) according to previ-
ously described protocol. To detect Tau aggregation, cells 
were fixed with 4% paraformaldehyde (PFA) containing 
2% sucrose and 1% Triton X-100 for 15 min to remove 
soluble proteins. After washing with PBS, aggregated Tau-
GFP was analyzed microscopically. To detect the effect of 
Otub1, USP5, and USP9x overexpression or knockdown 
on Tau aggregation, stably Tau-expressing QBI-293 cells 
were transfected with plasmid and empty vector or siRNA 
in 24-well plates. At 24 h after transfection, the growth 
medium was replaced with OptiMEM, and sonicated Tau 
seeds (10 μM) were added to BioPORTER® single-use 
tubes and added to cells. Three days after seeding, Tau-
GFP aggregation was measured by microscopy.
In vitro Tau aggregation assay in primary neurons was 
performed as described previously [65]. Tau seeds (10 nM) 
were added at DIV3 and DIV6 to primary cortical neu-
ronal cultures (PNC) from P0 heterozygous TauP301S 
pups. To detect the effect of Otub1 on Tau aggregation in 
primary neurons, AAV–Otub1 and AAV–GFP infections 
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were carried out at DIV3, Tau seeds (10 nM) were added 
at DIV6 and DIV9, and cells were fixed at DIV12 with 
4% PFA containing 2% sucrose and 1% Triton X-100 for 
15 min to remove soluble proteins. After washing with 
PBS, aggregated Tau-GFP was detected under microscope.
Immunofluorescence microscopy assay
At indicated times after infection, cells were washed by 
phosphate-buffered saline (PBS) for three times and fixed 
with 4% paraformaldehyde in PBS for 15 min at room tem-
perature (RT). For stringent extraction to detect aggregated 
Tau, 1% Triton X-100 (4% PFA, 2% sucrose) was used. 
Cells were briefly permeabilized in PBS/0.2% Triton X-100, 
then blocked in blocking solution (PBS containing 10% fetal 
calf serum and 0.1% Triton X-100). Primary and secondary 
antibody incubations were performed in blocking solution 
overnight at 4 °C or 1 h at RT using the indicated antibodies 
and goat anti-mouse IgG1 or goat anti-rabbit IgG1 secondary 
antibody coupled to Alexa® 488, Alexa® 568 or Alexa® 647. 
Cells were visualized using a digital inverted fluorescence 
microscope (EVOS-xl auto microscope).
Tau interactome mapping
Total mouse brain homogenates were used for coimmunopre-
cipitation in combination with three different polyclonal anti-
Tau antibodies and control antibodies that were cross-linked 
to Sepharose beads. Mass spectrometry procedures were 
performed essentially as previously reported [4]. A detailed 
description of the Tau interactome mapping procedure is pro-
vided in the Supplemental Experimental Procedures.
Results
Tau interactome mapping identifies Tau‑interacting 
proteins in mouse brain, including Otub1 as a potential 
Tau modifier
To identify Tau-interacting proteins with Tau-modifying 
potential, we performed Tau interactome mapping of 
endogenous Tau in mouse brain (Fig. 1) using a proteomic 
approach [3, 5]. Hereto, iTRAQ-based quantitative mass 
spectrometry was used in combination with differential 
coimmunoprecipitation of endogenous Tau from mouse 
brain. The use of isobaric isotope labels allows side-by-
side quantitative comparison of up to four different samples 
[76] (Fig. 1a). Four Tau immunoprecipitation experiments 
were performed using three different anti-Tau antibod-
ies and two different control non-Tau-capturing antibod-
ies for differential analysis (Fig. 1a). Statistical tools were 
applied to score proteins for selective coprecipitation with 
Tau. Retrieval of several well-characterized Tau-interacting 
proteins validated the experimental approach (Fig. 1b). 
These included several tubulin isoforms [41, 75, 79], dif-
ferent components of the dynactin complex [47], enzymes 
modifying Tau phosphorylation, and members of the heat 
shock protein family, i.e., Hsc70 (Hspa8), Hsp70 (Hspa4), 
and Hsp110 (Hsp110) [18, 30, 57]. In addition, we iden-
tified many new putative Tau interactors, based on their 
significant enrichment in anti-Tau immunoprecipitation 
compared with control immunoprecipitations (Tables S1, 
S2). The full Tau interactome is presented in Supplemen-
tary Tables S1–S4. Gene ontology and STRING analysis 
were performed (Fig. S1; Table S3), and candidate interac-
tors grouped according to their function (Fig. 1c; Table S4) 
to yield new insights into the pathophysiological role of 
Tau. Within this project, we focused on proteins involved 
in regulation of Tau ubiquitination and its degradation by 
the ubiquitin proteasome system, generally considered to 
be involved in degradation of small soluble proteins. We 
focused particularly on Tau deubiquitination and identified 
three major candidate deubiquitinating enzymes, including 
Otub1, USP5, and USP9x, with Otub1 as the strongest Tau 
interactor according to statistical analysis.
Otub1 increases Tau stability and increases Tau 
aggregation in a well‑characterized cellular Tau 
aggregation model
To analyze whether Tau-interacting proteins, identified by 
the Tau interactome mapping, exerted modifying effects 
on Tau aggregation, we used a well-validated cellular 
Tau seeding model [24, 65, 72]. We analyzed the effect 
of the three identified candidate DUBs on Tau aggrega-
tion in vitro. In this assay, QBI cells stably expressing the 
longest human Tau isoform (2N4R), with the aggregation-
prone P301L mutation and GFP tagged, were used in 
combination with preformed preaggregated synthetic Tau 
seeds consisting of Tau fragments harboring P301L mutant 
(myc-K18/P301L) to induce monomeric Tau aggregation. 
In this assay, addition of Tau seeds induces robust aggrega-
tion of monomeric human Tau, as assessed by cytological 
analysis following permeabilization with 1% Triton X-100 
to remove soluble forms of Tau while retaining aggre-
gated hyperphosphorylated Tau (Fig. 2a), as previously 
demonstrated and confirmed biochemically (Fig. S2) [65, 
72]. Expression of the candidate deubiquitinases Otub1, 
USP5, and USP9x in this assay demonstrated significantly 
increased Tau aggregation following expression of Otub1 
(Fig. 2a; Fig. S3), not observed following expression of 
USP5 or USP9x (Fig. S3). Next, we knocked down Otub1 
in the Tau seeding assay, using two siRNAs of Otub1 with 
different knockdown efficiency. Endogenous Otub1 deple-
tion significantly inhibited Tau aggregation, with the level 
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of inhibition correlating with the level of knockdown effi-
ciency, while use of a control siRNA did not affect levels 
of Otub1 nor aggregation efficiency (Fig. 2b). Combined, 
these data indicate that Otub1 affects Tau aggregation in a 
well-characterized Tau-seeded Tau aggregation model.
Since Otub1 is a deubiquitinase, known to regulate the 
stability of many crucial proteins in different cellular pro-
cesses [23, 26, 32, 44, 66], we assessed whether Otub1 
affected Tau stability by measuring Tau half-life following 
addition of the protein synthesis inhibitor cycloheximide 
Fig. 1  iTRAQ mass spec-
trometry-based Tau interac-
tome mapping in mouse brain 
identifies well-characterized and 
novel Tau-interacting proteins. a 
Four immunoprecipitation (IP) 
experiments were performed 
using three anti-Tau and two 
control antibodies as indicated 
(left panel iTRAQ experimental 
layout; right panel detail of the 
four experiments performed). 
b Graphical display of anti-Tau 
immunoprecipitation (IP) data. 
Results of anti-Tau hTau24 
(X-axis) IPs are compared with 
results of anti-Tau hTau21 IPs 
(Y-axis). Results are shown as 
log2 of ratio between quantifica-
tion of protein immunoprecipi-
tated with anti-Tau and control 
antibodies. Only proteins spe-
cifically precipitated with anti-
Tau antibodies are displayed 
[known Tau interactors (green 
dots); Otub1 (purple dot)]. 
Significantly enriched proteins 
with only one of the two 
antibodies are artificially drawn 
below the axes. Statistical tools 
were applied to identify a list of 
Tau-interacting proteins from 
the differential co-IP analysis 
in the four experiments. c Fol-
lowing gene ontology analysis, 
candidate Tau interactors were 
grouped according to their 
function; a weighted (font size) 
presentation of the interac-
tors (gene nomenclature) is 
displayed. The complete list 
of Tau-interacting proteins is 
provided in Tables S1–S4, and 





(CHX). Knockdown of Otub1 increased Tau turnover, cor-
relating with the decrease in expression of Otub1 obtained 
by the different siRNAs (Fig. 2c). Taken together, our data 
indicate that Otub1, a deubiquitinating enzyme, is a novel 
positive regulator of Tau aggregation and Tau stability 
in vitro, in a nonneuronal cell line.
Otub1 increases total Tau concentration and Tau 
phosphorylation in primary neurons
We next analyzed the modulatory effect of Otub1 on Tau in 
primary neurons, as relevant cell type for the study of Tauopa-
thies and AD. Hereto, primary cortical neurons, derived from 
TauP301S transgenic pups (PS19) [65, 81], were infected 
with AAV–Otub1–GFP or AAV–GFP driving neuron-specific 
expression. Immunocytological analysis with AT8 antibody 
against phosphorylated Tau (Ser202/Thr205) demonstrated 
that Otub1 expression drastically increased phospho-Tau 
(p-Tau Ser202/Thr205) in primary neurons compared with 
GFP expression (Fig. 3a). Biochemical analysis confirmed 
a sharp increase of phosphorylated Tau at Ser202/Thr205 in 
Otub1-infected primary neurons (Fig. 3b). Otub1 also signifi-
cantly increased total Tau protein level compared with GFP 
control (Fig. 3b). This increase was, however, less robust than 
the increase in AT8-positive Tau, as reflected by the ratio of 
AT8/total Tau. Taken together, we conclude that overexpressed 
Otub1 in primary neurons expressing TauP301S increased 
total Tau and induced a robust increase in AT8-positive Tau.
Otub1 enhances Tau oligomerization and Tau‑seeded 
Tau aggregation in primary neurons
We next analyzed the effect of Otub1 in a validated Tau 
aggregation assay in primary neurons [65, 81]. Addition of 
Tau seeds allows bypass of the lag phase of Tau aggrega-
tion, resulting in recruitment of soluble Tau into insoluble 
Tau aggregates, reflected in a robust detergent-resistant AT8 
(phosphorylated Tau) signal throughout soma and neurites 
(Fig. 4a, Fig. S2a). We used this well-characterized assay 
to analyze a potential effect of Otub1 on Tau aggregation 
in TauP301S cortical primary neurons using AAV-driven 
expression of Otub1 or GFP for control. Otub1 expres-
sion strikingly enhanced detergent-resistant AT8-positive 
Tau accumulation compared with GFP-infected neurons 
(Fig. 4b), indicating that Otub1 increased Tau-seeded Tau 
aggregation in primary neurons, corroborating the results 
obtained in a nonneuronal cell line.
To measure the effect of Otub1 expression on oligomeric 
Tau forms, we performed Western blotting analysis in non-
reducing conditions, following AAV-driven expression of 
Otub1 and GFP, in absence of Tau seeding. This revealed 
a significant increase of oligomeric Tau forms in AAV–
Otub1-infected neurons compared with AAV–GFP-infected 
neurons (Fig. 4c). In addition, we found robust induction 
of a (homo- or heterotypic) Tau complex (Tauc), which 
was strongly detected in AAV–Otub1-infected neurons but 
absent in AAV–GFP-infected neurons, indicating clearcut 
Otub1-induced modulation of Tau in neurons. The induc-
tion of oligomeric Tau forms was further confirmed using 
dot-blot analysis with T22 antibody (Fig. 4d), revealing a 
significant increase in oligomeric Tau following expression 
of Otub1.
Taken together, our data demonstrate that Otub1, iden-
tified as a Tau-interacting protein in the Tau interactome 
mapping, modulates Tau, by increasing Tau-seeded Tau 
aggregation, by formation of a Otub1-induced Tau complex 
Tauc, and by increasing the concentration of oligomeric Tau 
forms in primary neurons.
Otub1 but not Otub1‑C91A impairs Tau degradation 
by removing Lys48‑linked polyubiquitin chains 
from Tau in primary neurons
Previous studies have shown that Otub1 has dual functions 
in regulating both ubiquitin assembly and disassembly [77, 
78]. Otub1, as an isopeptidase, can remove Lys48-linked 
polyubiquitin chains from its substrates [17, 48, 74], but 
can also serve as an E2 enzyme inhibitor to impede Lys63-
specific polyubiquitin chain formation in a noncanonical 
manner [61]. Since Otub1 interacts with Tau and promotes 
phosphorylated and aggregated Tau levels in primary neu-
rons, we hypothesized that Otub1 could act as a Tau deu-
biquitinase, interfering with pathological Tau degradation 
and hence Tau aggregation. To test this assumption experi-
mentally, we analyzed the ubiquitination status of Tau by 
immunoprecipitation. Following AAV-driven expression of 
Otub1 or GFP in primary neurons, Tau proteins were pulled 
Fig. 2  Otub1 increases Tau stability and increases Tau aggregation 
in a well-characterized cellular Tau aggregation model. a QBI-293 
cells, stably expressing GFP-tagged TauP301L, were seeded with 
preaggregated synthetic Tau seeds to induce monomeric Tau aggre-
gation. Tau aggregation was assessed by stringent extraction using 
1% Triton X-100 to remove soluble proteins. Tau aggregation follow-
ing expression of Otub1 and control vector in QBI-293 cells reveals 
significant increase of Tau aggregation following Otub1 expression, 
demonstrated by quantitative analysis (n > 36 fields per condition; 
scale bar 200 μm; **p value <0.01). Otub1 overexpression was bio-
chemically validated using anti-Otub1 antibody. b Endogenous Otub1 
depletion using two different siRNAs of Otub1 significantly inhibited 
Tau aggregation, correlating with the level of knockdown efficiency, 
as demonstrated by quantitative analysis (n > 36 fields per condi-
tion; scale bar 200 μm; **p value <0.01; ***p value <0.001). Otub1 
knockdown efficiency was quantified by Western blotting using anti-
Otub1 antibody. c Endogenous Otub1 depletion using two different 
siRNAs of Otub1 significantly increased Tau turnover, measured fol-
lowing treatment with cycloheximide (CHX, 20 μg/ml) for indicated 
times to inhibit protein synthesis and analyzed by immunoblotting. 





Fig. 3  Otub1 increases total Tau concentration and Tau phosphoryla-
tion in primary neurons. a Immunofluorescence staining of primary 
TauP301S neurons infected with AAV–Otub1 or AAV–GFP using 
AT8 recognizing Tau phosphorylated at the pathologically relevant 
epitope Ser202/Thr205. Higher magnifications of AT8-stained neu-
rons of Otub1- and GFP-expressing neurons are presented. Quantifi-
cation of staining intensities are presented as mean ± standard error 
of the mean (SEM) (***p value <0.001; n = 3 different infections; 
for each infection, three repetitions are analyzed). b Western blot 
analysis of AAV-infected primary TauP301S neuron lysates using 
AT8 and total Tau antibodies. Actin was used as loading control on 
each blot. Ratio of AT8/Tau indicates the preferential effect of Otub1 
on Phospho-Tau (AT8) (*p value <0.05; **p value <0.01; ***p value 




Fig. 4  Otub1 enhances Tau oligomerization and Tau-seeded Tau 
aggregation in primary neurons. a Tau aggregation assay in TauP301S 
primary neurons. Addition of Tau seeds resulted in phosphorylated 
Tau (Ser202/Thr205) staining in soma and neurites, resisting strin-
gent extraction with 1% Triton X-100 (n > 36 fields per condition; 
scale bar 200 μm; ***p value <0.001). b Primary TauP301S neurons 
were infected with AAV–Otub1 or AAV–GFP three days after cultur-
ing, and seeded 1 and 4 days postinfection, respectively. At 7 days 
after transduction, neurons were fixed and stringently extracted 
for analysis of aggregated Tau. Immunofluorescent staining using 
AT8 (Ser202/Thr205) after extraction is shown, demonstrating Tau 
aggregation. Quantification is presented as mean ± SEM (n = 3 dif-
ferent experiments; for each infection, 36 fields per condition were 
analyzed; scale bar 200 μm; ***p value <0.001). c Western blotting 
analysis of primary neuron extracts in nonreducing conditions, fol-
lowing AAV-driven expression of Otub1 and GFP, reveals increased 
monomeric Tau and increased oligomeric forms of Tau (detected as 
high-MW smears) in Otub1-overexpressing neurons (n = 3 different 
experiments; for each infection, three repetitions were analyzed; *p 
value <0.05; **p value <0.01). Induction of a Tau complex (homo- 
or heteromeric)—denoted Tauc—is clearly noticed following AAV–
Otub1 but not AAV–GFP infection. d Dot-blot analysis of primary 
neuron lysates using oligomeric Tau-specific antibody T22 was per-
formed and quantitatively analyzed following normalization to total 
Tau (dot-blot analysis) (mean ± SEM; n = 8 infection for each 
group; *p value <0.05)
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Fig. 5  Otub1 but not Otub1-C91A increases Tau stability by remov-
ing Lys48-linked polyubiquitin chains from Tau in primary neurons. 
a Primary neurons from TauP301S mice were infected with AAV–
Otub1 or AAV–GFP. At 7 days after infection, Tau proteins were 
immunoprecipitated with Tau antibody and analyzed by linkage-
specific ubiquitin (Ub-Lys48, Ub-Lys63) immunoblotting. A repre-
sentative blot is shown; quantification of three different experiments 
is presented (***p value <0.001). b Otub1-WT or catalytically dead 
mutant (C91A), N-terminal truncated mutant (N-T), and GFP control 
were expressed in primary TauP301S neurons. Immunoprecipitation 
was performed using Tau antibody, and Lys48-linked polyubiquitin 
chain formation was detected using Ub-Lys48 antibody. c Primary 
TauP301S neurons were infected with AAV–Otub1 compared with 
AAV–GFP. Five days later, neurons were treated with 10 µM protein 
synthesis inhibitor cycloheximide (CHX) for different durations up 
to 36 h as indicated. Similar comparison was performed for primary 
neurons from TauP301S mice infected with AAV–Otub1-WT com-
pared with AAV–Otub1-C91A. The rate of Tau turnover was quan-
tified using Western blot analysis. Actin served as loading control 
within each group. Quantification was performed on three independ-
ent experiments (**p value <0.01; ***p value <0.001)
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down, and Lys48- and Lys63-linked polyubiquitination of 
Tau was measured by linkage-specific ubiquitin antibod-
ies. To enrich ubiquitinated proteins, proteasome inhibitor 
was added to the medium 6 h before harvesting. Otub1 dis-
played strong preference for disassembling Lys48-linked 
polyubiquitin chains, while leaving Lys63-linked polyubiq-
uitin chains unaffected (Fig. 5a). Analysis of a catalytically 
dead mutant with a C91A mutation revealed no effect on 
Lys48-linked polyubiquitination of Tau. Conversely, AAV-
driven expression of N-terminally truncated Otub1 sig-
nificantly decreased Lys48-linked polyubiquitin chains of 
Tau (Fig. 5b), demonstrating that the N-terminal domain 
of Otub1, which is crucial for its noncanonical role, is not 
involved in regulation of Tau ubiquitination.
To confirm the effect of Lys48-linked polyubiquitination 
change on Tau degradation, TauP301S neurons were infected 
with AAV–Otub1–GFP or AAV–GFP, and subsequently treated 
with protein synthesis inhibitor cycloheximide (CHX) for dif-
ferent durations up to 36 h to quantify the rate of Tau turnover 
using Western blot. We found that Tau degradation was signifi-
cantly impaired in primary neurons infected with Otub1 WT, 
but not with catalytically dead mutant C91A, compared with 
GFP control. These results indicate that Otub1 regulates Tau 
degradation, dependent on its catalytic activity (Fig. 5c).
Fig. 6  The effect of Otub1 on 
Tau phosphorylation is depend-
ent on Otub1 catalytic activity. 
a Immunofluorescence staining 
of TauP301S primary neurons 
infected with AAV–Otub1 wild 
type (WT), catalytically dead 
mutant (C91A) or N-terminal 
truncation (N-T) using phospho-
Tau antibody AT8 (Ser202/
Thr205). Quantification of 
staining intensities is presented 
as mean ± SEM (***p value 
<0.01; n = 3 different infec-
tions; for each infection, three 
repetitions are analyzed). b 
Western blot analysis of AAV-
infected primary neurons lysates 
using AT8 antibody. Actin was 
used as loading control (**p 
value <0.01; n = 3 different 
infections; for each infection, 
three repetitions were analyzed)
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We further analyzed whether catalytically dead Otub1-
C91A could affect Tau phosphorylation in primary neurons 
expressing TauP301S. AAV-driven expression of Otub1-
C91A did not increase AT8-positive Tau, in contrast to 
expression of wild-type Otub1 and the N-terminally trun-
cated form of Otub1. This was demonstrated by immuno-
fluorescence staining (Fig. 6a) and confirmed by biochemi-
cal analysis (Fig. 6b).
Taken together, our data prove that Otub1 can remove 
Lys48-linked polyubiquitin chains from Tau in a catalytic 
activity-dependent manner, implicating the canonical path-
way. Consequently, Otub1-dependent deubiquitination 
inhibits Tau degradation through the proteasome pathway 
and prolongs its half-life, leading to accumulation of patho-
logical forms of Tau.
Otub1 promotes Tau phosphorylation 
and oligomerization in vivo in Tau transgenic mice
To investigate the effect of Otub1 on Tau in vivo, AAV–Otub1 
and AAV–GFP were bilaterally intraventricularly injected 
into TauP301S transgenic pups (P0), resulting in widespread 
expression of Otub1 and GFP in cortical neurons at 2 months 
of age (Fig. 7a). Immunostaining with AT8 antibody revealed 
abundant AT8-positive neurons in AAV–Otub1-injected mice, 
absent in AAV–GFP-infected mice (Fig. 7a), at 2 months 
postinjection. Biochemical analysis further confirmed 
increased AT8-positive Tau by Otub1 expression (Fig. 7b), 
with AT8 phosphorylated Tau more robustly increased than 
total Tau, as reflected by the AT8/total Tau ratio. Cortex 
homogenates from TauP301S transgenic mice injected with 
AAV–Otub1 and control mice injected with AAV–GFP were 
analyzed under nonreducing condition. This revealed a signif-
icant increase of monomeric Tau and oligomeric Tau in AAV–
Otub1-injected mice compared with AAV–GFP-injected mice 
(Fig. 7c). Similarly as in primary neurons, Tauc (a homo- or 
heterotypic Tau complex) was robustly induced in AAV–
Otub1- but not AAV–GFP-injected mice, strongly confirm-
ing Otub1-induced modulation of Tau in brain (Fig. 7c). To 
further confirm the increased concentration of oligomeric Tau 
forms following Otub1 expression, dot-blot analysis using 
oligomeric Tau-specific antibody T22 was performed. This 
revealed significantly increased oligomeric Tau in AAV–
Otub1-injected mice compared with AAV–GFP-injected con-
trol cases (Fig. 7d).
The effect of Otub1 on Tau phosphorylation 
and oligomerization in vivo is dependent on its catalytic 
function
To further assess the requirement for catalytically active 
Otub1 and the presence of the catalytically conserved C91 
of Otub1, for accumulation of pathological Tau forms 
in vivo, we performed P0 injections of AAV–Otub1-C91A 
or AAV–Otub1-N-terminal truncated mutant, and AAV–
Otub1-WT in TauP301S mice. Immunostaining and bio-
chemical analysis, 2 months postinjection, unambiguously 
revealed that the catalytically dead mutant C91A did not 
affect AT8-stained Tau in vivo, while N-terminal truncated 
mutant of Otub1 increased AT8-positive Tau in vivo, simi-
larly as wild-type Otub1 (Fig. 8).
To further analyze the requirement for catalytically 
active Otub1 for induction of oligomeric Tau forms, brain 
extracts of AAV-infected TauP301S mice were biochemi-
cally analyzed 2 months postinjection, under nonreducing 
condition. This revealed significantly increased oligomeric 
Tau forms, following expression of wild-type Otub1, but 
not following expression of GFP or of the catalytically 
inactive form of Otub1 (C91A) (Fig. 8c). This was further 
confirmed by dot-blot analysis using T22 antibody recog-
nizing oligomeric Tau forms (Fig. 8d). These data indicate 
that expression of catalytically active Otub1 is required for 
accumulation of phosphorylated Tau and oligomeric Tau 
forms.
Noteworthy, to analyze whether endogenous Otub1 is 
modulated in conditions of accumulating pathological Tau 
forms, we took advantage of our microarray analysis per-
formed for a different project in which we analyzed time-
dependent changes in gene expression in hippocampus fol-
lowing Tau-seeded Tau aggregation in Tau transgenic mice. 
Interestingly, Otub1 expression is gradually downregulated 
with increasing Tau-seeded Tau aggregation (Fig. S4a), which 
could be considered as a protective mechanism. Furthermore, 
Fig. 7  Otub1 increases concentrations of phosphorylated Tau and 
Tau oligomers in vivo in Tau transgenic mice. a Immunohistochemi-
cal staining of cortex of TauP301S transgenic mice injected with 
AAV–Otub1 or AAV–GFP at P0 and analyzed at 2 months. Repre-
sentative images of AAV-driven expression of Otub1 and GFP are 
presented (green). Representative AT8 stainings are presented (red). 
Quantitative analysis is presented as mean ± SEM (n = 9 mice for 
each group; 3–5 sections were examined for each mouse; 9–12 fields 
were quantified for each section; scale bar 400 μm; ***p value 
<0.001). b Western blotting analysis of phosphorylated Tau and total 
Tau in cortex homogenates of AAV–Otub1- and AAV–GFP-injected 
mice, using AT8 (Ser202/Thr205) and anti-Tau antibody, is presented. 
Quantitation was performed on n = 9 mice for each group; the AT8/
Tau ratio indicates the preferential effect of Otub1 on Tau phospho-
rylation (*p value <0.05). c Western blotting analysis of mice cor-
tex homogenates in nonreducing condition reveals clear induction 
of oligomeric forms of Tau (detected as high-MW smears), as well 
as monomeric Tau protein level increase in TauP301S mice injected 
with AAV–Otub1 (n = 9 mice for each group; *p value <0.05; **p 
value <0.01). Induction of a Tau complex (homo- or heteromeric) 
of ~120 kDa—denoted Tauc—is clearly detected following AAV–
Otub1 but not AAV–GFP infection. d Dot-blot analysis of mice cor-
tex homogenates using oligomeric Tau-specific antibody T22 is pre-
sented. Quantitative analysis was performed following normalization 







analysis of hippocampal gene expression in aging mice, using 
publicly available data (NCBI database GDS2082) [73], indi-
cates a significant increase in Otub1 expression with aging 
(Fig. S4b). The latter suggests that increased expression of 
Otub1 with aging might contribute to increased risk for accu-
mulation of pathological Tau forms with aging.
Discussion
Accumulation of aberrantly folded proteins is common to 
many neurodegenerative disorders, including AD, mak-
ing (dys)regulation of proteostasis not only a potentially 
implicated pathogenetic mechanism, but most impor-
tantly an attractive therapeutic target. In AD, symptom 
progression strongly correlates with progression of Tau 
pathology, with early, soluble, oligomeric forms of Tau 
generally considered as toxic culprits. Aberrant protein 
degradation occurs through either the ALS or UPS, with 
the former mainly involved in degradation of large insol-
uble protein aggregates, while the latter is preferentially 
involved in clearance of smaller soluble forms, being the 
focus of this work. In view of the importance of the UPS 
in AD, Tau-ubiquitinating enzymes have been identified, 
while Tau deubiquitination has received less attention. 
Starting from a Tau interactome mapping, we identified 
here for the first time Otub1 as a novel Tau deubiquit-
inase, affecting accumulation of pathological forms of 
Tau in vitro and in vivo.
Here, we present a proteome-wide screening approach 
to identify Tau-interacting proteins, as a basis to gain 
insight into Tau pathophysiology and to identify Tau modi-
fiers with therapeutic potential. Proteome-wide screening 
approaches are increasingly used—in analogy to genome-
wide screening approaches—to gain novel insights from an 
unbiased starting point for drug discovery and fundamen-
tal science [3, 10, 27, 58, 62]. We used an iTRAQ-based 
approach to identify proteins interacting with endogenous 
Tau from mouse brain. The validity of our approach is 
reflected in the identification of several well-characterized 
Tau-interacting proteins and the current identification of 
Otub1 as a Tau deubiquitinase. The presented Tau interac-
tome provides important information, extending beyond the 
current work, providing the basis for novel insights into the 
pathological role of Tau and to identify novel Tau-directed 
targets.
Here, we validated this approach and identified for the 
first time Otub1 as a novel Tau deubiquitinase, based on the 
Tau interactome map. Accumulating evidence implicates 
dysregulated proteostasis and a dysregulated UPS in AD, as 
highlighted in the “Introduction.” Different types of poly-
ubiquitination of Tau, including Lys48 and Lys63 linked, 
have been identified in AD patients by mass spectrometry 
and immunological analysis [13, 49–51, 56]. Interestingly, 
we here identified Otub1 as a Tau deubiquitinase which 
decreases the levels of Lys48- but not Lys63-linked poly-
ubiquitin chains on Tau, increasing Tau stability in neurons. 
Our finding is in line with previous reports showing that 
Otub1 has preference for Lys48-linked polyubiquitination 
[17, 48, 74] and functions as a regulator of protein turnover 
[23, 26, 32, 44, 66]. Mutation of the catalytically conserved 
cysteine (C91) abolished its role in Tau polyubiquitination, 
further confirming the crucial role of its catalytic capacity 
for its involvement in the regulation of Lys48 polyubiquit-
ination on Tau. Otub1 has also been found to have a nonca-
nonical role in DNA damage response by impeding Lys63 
polyubiquitin chain formation [53, 77, 78], but no effect of 
Otub1 on Lys63 polyubiquitination of Tau nor implication 
of the N-terminal part of Otub1 was demonstrated.
Notably, the effect of polyubiquitination modification is 
determinant for the fate of its substrate. Lys48 polyubiq-
uitin chains act as a proteasomal degradative signal, while 
Lys63-linked ubiquitin modification has been proposed 
to contribute to biogenesis of inclusions and clearance of 
larger aggregates by autophagy [36, 55, 68, 80]. Although 
soluble Tau forms as well as large insoluble aggregated Tau 
forms can be polyubiquitinated [13, 49, 50], higher-order 
protein aggregations are unlikely to pass through the nar-
row proteasome opening, and they are normally seques-
trated into inclusions or aggresomes and cleared through 
Fig. 8  The effect of Otub1 on Tau phosphorylation and oligomeri-
zation in vivo is dependent on its catalytic function. a Immunohis-
tochemical staining of cortex of TauP301S transgenic mice injected 
with AAV–Otub1 (WT), catalytically dead mutant (C91A) or 
N-terminal truncation (N-T) at P0 and analyzed at 2 months. Rep-
resentative images of AAV-driven expression of Otub1 (wild type, 
C91A, NT) are presented (green). Representative AT8 stainings 
are presented (red) for each group (3–5 sections were examined 
for each mouse; 9–12 fields were quantified for each section; scale 
bar 400 μm, ***p value <0.001). b Western blotting analysis was 
used to analyze phosphorylated Tau in cortex homogenates of mice 
injected with AAV–Otub1 wild type or two mutants, AAV–Otub1 
C91A and AAV–Otub1 N-T, using AT8 (Ser202/Thr205) antibody 
(n = 3 mice for each group; ***p value <0.001). c Western blotting 
analysis of cortex homogenates from TauP301S mice injected with 
AAV–Otub1 wild type, with AAV–Otub1 C91A, or AAV–GFP in 
nonreducing condition using Tau antibody is presented. This reveals 
a clear increase in oligomeric forms of Tau only in TauP301S mice 
injected with AAV–Otub1 wild type, while not in AAV–Otub1 C91A- 
or AAV–GFP-injected TauP301S mice (n = 3 mice for each group; 
*p value <0.05; **p value <0.01). Monomeric Tau increased, less 
strongly compared with oligomeric Tau, in TauP301S mice injected 
with AAV–Otub1 wild type, compared with AAV–Otub1 C91A- or 
AAV–GFP-injected TauP301S mice (n = 3 mice for each group; 
*p value <0.05; ***p value <0.001). d Dot-blot analysis of cortex 
homogenates from TauP301S mice injected with AAV–Otub1 wild 
type, with AAV–Otub1 C91A, or AAV–GFP using oligomeric Tau-
specific antibody T22 is presented. Quantitative analysis was per-
formed following normalization to total Tau (dot-blot analysis) (n = 3 




the ALS. Recently, several lines of evidence have indi-
cated selective autophagy using Lys63-linked polyubiq-
uitin chains as a cargo recognition signal [36, 55, 68, 80]. 
In our experiments, we found that Otub1 only influences 
Lys48 polyubiquitination but not Lys63-linked polyubiqui-
tin chains of Tau, and therefore would be rather involved 
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in clearance of smaller soluble forms of Tau through the 
proteasome.
These findings are further strengthened by our assess-
ment of the effect of Otub1 on Tau metabolism. We demon-
strate that Otub1-dependent Tau deubiquitination is linked 
to accumulation of Tau phosphorylated at the pathologi-
cally relevant AT8 epitope—used for Braak staging—and 
accumulation of oligomeric soluble forms of Tau, which 
have been considered to be toxic culprits. Hence, overex-
pressed Otub1, which regulates Lys48-linked polyubiq-
uitination of Tau, promotes accumulation of abnormally 
phosphorylated Tau and oligomeric Tau, both in Tau trans-
genic mice and in primary neurons. These findings are in 
line with previously published findings. Depletion of CHIP 
in Tau mice leads to significant accumulation of ubiquitin-
negative, and phosphorylated soluble Tau species [16]. In 
a nonneuronal cell line which overexpresses the longest 
human Tau isoform, proteasome inhibitor treatment sta-
bilizes phosphorylated and aggregated Tau species which 
arise from Tau phosphatase PPA inactivation and normally 
decay within 24 h [21]. In a triple transgenic mouse model, 
amyloid β-peptide (Aβ) immunotherapy leads to clearance 
of early soluble Tau forms by the UPS, but not of late Tau 
aggregates [54]. Along the same vein, molecular chaperon 
FKBP51, together with Hsp90, increase Tau oligomer for-
mation by inhibiting Tau degradation through the protea-
some in a mouse model [8]. In line with these reports, our 
work corroborates regulation of the early pathological Tau 
forms by the UPS, including deubiquitination as an impor-
tant modulator.
Our data are important in view of the fact that early oli-
gomeric forms of Tau are generally considered to be toxic 
culprits in AD and related Tauopathies. We have previ-
ously shown in a Tau seeding assay in in vitro and in vivo 
models that neuronal dysfunction correlated strongly with 
early pathological forms of Tau rather than with full-
blown mature NFTs [65]. Previous studies using elegant 
approaches have indicated that the Tau aggregation process 
and early pathological forms rather than full-blown NFTs 
correlate with neuronal dysfunction [6, 11, 12, 15, 33, 37, 
39, 40, 59, 60, 67]. The detrimental role of Tau oligomers 
in neuronal function and behavior was further demonstrated 
using acute injection of oligomeric Tau and immunization 
with anti-Tau oligomeric antibodies [11, 12, 39, 40]. Taken 
together, these data highlight the importance of targeting 
early oligomeric Tau forms as pathogenetic culprits, and 
hence the importance of the demonstrated effect of Otub1 
on soluble oligomeric forms of Tau.
Interestingly, we show that the conserved catalytic 
cysteine (C91) of Otub1 is crucial for accumulation of 
hyperphosphorylated Tau and oligomeric Tau species. This 
finding is not only important as an internal control but also 
in the context of drug development, providing a druggable 
target. It must be noted that upstream modulators of Otub1, 
mechanisms regulating Otub1 activity, expression and 
probably the binding of Otub1 to chaperone molecules 
must be considered as potential therapeutic targets as well. 
Regulation of key proteins via recruitment of distinct E3 
ligases or DUBs mediated by specific adaptor proteins is 
common in many cellular pathways. While the mechanisms 
upstream of Otub1 remain unknown, they may provide 
additional therapeutic targets. Inhibition of deubiquitinases 
as therapeutic targets is attracting increasing attention for 
different diseases, including cancer. Our findings identify-
ing Otub1 as a Tau deubiquitinase affecting pathological 
forms of Tau in vitro and in vivo may therefore yield new 
perspectives for therapy.
Taken together, in this work we present a Tau interac-
tome map, which yields a basis for novel insights into Tau 
biology and its pathological role, validated by and extend-
ing beyond our current work. We furthermore provide novel 
insight into the link between the UPS and AD and open 
new avenues for development of small-molecule inhibitors 
specifically targeting accumulation of pathological forms 
of Tau in AD and related Tauopathies.
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